Acute Anterior Uveitis following Pfizer-BioNTech mRNA COVID-19 (BNT162b2) Vaccination – Case Report

Article Sidebar

29-Mar-6345.pdf
Published Apr 3, 2025
DOI: https://doi.org/10.18103/mra.v13i3.6345

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Yigit C. Akduman, MD
SSMHealth Medical Group, Department of Ophthalmology, Saint Louis University, School of Medicine
Pamela Martin, MD
Department of Ophthalmology, University of Florida, Gainesville
William J. Anderson, MD
SSMHealth Medical Group, Department of Ophthalmology, Saint Louis University, School of Medicine
Sabrina M. Shultz, OD
Quantum Vision, 12 Professional Park Dr, Maryville, IL, USA
Jinghua Chen, MD
Department of Ophthalmology, University of Florida, Gainesville
Henry J. Kaplan, MD
SSMHealth Medical Group, Department of Ophthalmology, Saint Louis University, School of Medicine; Department of Biochemistry & Molecular Biology, Saint Louis University, School of Medicine
Niloofar Piri, MD
SSMHealth Medical Group, Department of Ophthalmology, Saint Louis University, School of Medicine
Niloofar Piri, MD
SSMHealth Medical Group, Department of Ophthalmology, Saint Louis University, School of Medicine

Abstract

Background: Vaccine-associated intraocular inflammation has been reported with several vaccines, including the Pfizer-BioNTech mRNA COVID-19 (BNT162b2) vaccine. While rare, these ocular adverse events warrant further investigation to better understand their clinical course, ideal management, and long-term outcomes. Anterior uveitis has been the most commonly reported manifestation following mRNA COVID-19 vaccination, but optimal treatment strategies and risk of recurrence remain unclear.


Aims: To report three cases of acute anterior uveitis occurring within weeks of COVID-19 vaccination, assess their response to treatment and follow up course, and review existing literature on vaccine-associated uveitis.


Methods: This case report analyzes three patients who developed acute anterior uveitis following COVID-19 vaccination. All patients underwent a comprehensive ophthalmic evaluation at presentation, including best-corrected visual acuity, slit-lamp examination, intraocular pressure measurement, and dilated fundus exam. These patients were managed with topical corticosteroids and were followed over the course of 30 months to assess response to treatment as well as any recurrence or complications.


Results: Each case of uveitis was successfully treated with topical corticosteroids, leading to complete resolution of inflammation without requiring systemic immunosuppressants. One patient experienced a mild recurrence eight weeks after the second vaccine dose, which was controlled with a second course of topical corticosteroids. No further recurrences were observed with long-term follow-up extending up to 30 months. Laboratory and imaging evaluations were negative for systemic inflammatory or infectious causes.


Conclusion: All three cases of acute anterior uveitis after COVID-19 vaccination responded well to topical corticosteroids, with no evidence of persistent or recurrent inflammation or long-term complications. These findings suggest that, in the absence of previously documented systemic autoimmune disease or other concerning features, COVID-19 vaccine associated acute anterior uveitis can be effectively managed with topical therapy alone, without the need for extensive systemic workup. Larger studies are needed to further investigate these findings and management strategies.

Keywords: Acute anterior uveitis, COVID-19 vaccination, mRNA vaccine, Ocular inflammation, Pfizer-BioNTech

Article Details

How to Cite
AKDUMAN, Yigit C. et al. Acute Anterior Uveitis following Pfizer-BioNTech mRNA COVID-19 (BNT162b2) Vaccination – Case Report. Medical Research Archives, [S.l.], v. 13, n. 3, apr. 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6345>. Date accessed: 06 apr. 2025. doi: https://doi.org/10.18103/mra.v13i3.6345.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 13 No 3 (2025): Vol.13, Issue 3, March 2025
Section
Case Reports

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Cunningham ET Jr, Moorthy RS, Fraunfelder FW, Zierhut M. Vaccine-associated uveitis. Ocul Immunol Inflamm. 2019;27(4):517-520. doi:10.1080/09273948.2019.1626188.

2. Benage M, Fraunfelder FW. Vaccine-associated uveitis. Mo Med. 2016;113(1):48-52. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27039491.

3. Fraunfelder FW, Suhler EB, Fraunfelder FT. Hepatitis B vaccine and uveitis: an emerging hypothesis suggested by review of 32 case reports. Cutan Ocul Toxicol. 2010;29(1):26-29. doi:10.3109/15569520903427717.

4. Mudie LI, Zick JD, Dacey MS, Palestine AG. Panuveitis following vaccination for COVID-19. Ocul Immunol Inflamm. 2021;1-2. doi:10.1080/09273948.2021.1949478.

5. Mambretti M, Huemer J, Torregrossa G, Ullrich M, Findl O, Casalino G. Acute macular neuroretinopathy following coronavirus disease 2019 vaccination. Ocul Immunol Inflamm. 2021;1-4. doi:10.1080/09273948.2021.1946567.

6. Testi I, Brandao-de-Resende C, Agrawal R, Pavesio C, C-VOIES Group. Ocular inflammatory events following COVID-19 vaccination: a multinational case series. J Ophthalmic Inflamm Infect. 2022;12(1):4. doi:10.1186/s12348-021-00275-x.

7. Cherif YYS, Djeffal C, Abu Serhan H, et al. The characteristics of COVID-19 vaccine-associated uveitis: a summative systematic review. Vaccines (Basel). 2022;11(1):69. Published December 28, 2022. doi:10.3390/vaccines11010069.

8. Rabinovitch T, Ben-Arie-Weintrob Y, Hareuveni-Blum T, et al. Uveitis after the BNT162b2 mRNA vaccination against SARS-CoV-2 infection: a possible association. Retina. 2021;41(12):2462-2471. doi:10.1097/IAE.0000000000003277.

9. Pichi F, Aljneibi S, Neri P, Hay S, Dackiw C, Ghazi NG. Association of ocular adverse events with inactivated COVID-19 vaccination in patients in Abu Dhabi. JAMA Ophthalmol. 2021;139(10):1131. doi:10.1001/jamaophthalmol.2021.3477.

10. Kim J, Kwon HY, Ahn SJ. COVID-19 vaccine-associated uveitis in patients with a history of uveitis. JAMA Ophthalmol. 2024;142(6):522-528. doi:10.1001/jamaophthalmol.2024.0973.

11. Tomkins-Netzer O, Sar S, Barnett-Griness O, Friedman B, Shyriaieva H, Saliba W. Association between vaccination with the BNT162b2 mRNA coronavirus disease 2019 vaccine and noninfectious uveitis: a population-based study. Ophthalmology. 2022;129(10):1087-1095. doi:10.1016/j.ophtha.2022.05.015.

12. Lee YK, Huang YH. Ocular manifestations after receiving COVID-19 vaccine: a systematic review. Vaccines (Basel). 2021;9(12). doi:10.3390/vaccines9121404.

13. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389.

14. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577.

15. Chang MS, Kim HR, Kim S, et al. Noninfectious uveitis risk after COVID-19 vaccination: a nationwide retrospective cohort study. Am J Ophthalmol. 2024;258:22-31. doi:10.1016/j.ajo.2023.09.015.

16. Watad A, David P, Brown S, Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants and thyroid autoimmunity. Front Endocrinol (Lausanne). 2016;7:150. doi:10.3389/fendo.2016.00150.

17. Pan L, Zhang Y, Cui Y, Wu X. Bilateral uveitis after inoculation with COVID-19 vaccine: a case report. Int J Infect Dis. 2021;113:116-118. doi:10.1016/j.ijid.2021.09.075.

18. Sim HE, Hwang JH. New onset of acute uveitis following COVID-19 vaccination. Graefes Arch Clin Exp Ophthalmol. 2023;261:555-560. doi:10.1007/s00417-022-05798-0.

19. Watad A, Quaresma M, Brown S, et al. Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld's syndrome) - an update. Lupus. 2017;26(7):675-681. doi:10.1177/0961203316686406.

20. Wenande E, Garvey LH. Immediate-type hypersensitivity to polyethylene glycols: a review. Clin Exp Allergy. 2016;46(7):907-922. doi:10.1111/cea.12760.

21. Singh RB, Parmar UPS, Kahale F, Agarwal A, Tsui E. Vaccine-associated uveitis after COVID-19 vaccination: Vaccine Adverse Event Reporting System database analysis. Ophthalmology. 2023;130(2):179-186. doi:10.1016/j.ophtha.2022.08.027.

22. Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 mRNA vaccination and myocarditis in a Nordic cohort study of 23 million residents. BMJ. 2021;375:e068665. doi:10.1136/bmj-2021-068665.